Videos

Mease outlined positive efficacy and safety findings from multiple long-term follow-up trials of the biologic in people with PsA and AxSpA.

Delayed specialist referral can result in decades of unnecessary pain and joint damage for patients with gout.

Gout should be treated as a chronic disease, not just an episodic flare condition.

Medication adherence, access, and comorbidity management are critical to achieving target uric acid levels.

Elevated uric acid is modifiable, and long-term remission is attainable with appropriate pharmacologic and lifestyle interventions.

Gout is a systemic metabolic disease requiring proactive, individualized treatment plans beyond dietary modification.

Gout and CKD share a bidirectional relationship that complicates management and demands multidisciplinary care.

Uncontrolled gout is a progressive, genetically driven, systemic condition that requires individualized, evidence-based urate-lowering therapy and close clinical monitoring.

Sayna Norouzi, MD, reflects on the recent progress in the therapeutic pipeline for lupus nephritis.

Sayna Norouzi, MD, discusses results from a pair of trials examining QoL in patients with lupus from ERA 2025.

Nowak discussed some of the unique advantages inebilizumab offers for this population.

Blockmans discussed data supporting upadacitinib’s new indication and why the approval is important for patients with giant cell arteritis.

Mease discussed recent research on what matters in PsA care between patients and clinicians.

Mease discussed the expanding treatment landscape for PsA and how the field is integrating new biologics.

Furie discussed topline data from the REGENCY trial and key secondary endpoints.

Furie discussed his experiences in evaluating therapies such as rituximab and now obinutuzumab for lupus nephritis.

Davidow discussed how a new cohort study has helped support findings of an older European study and the need for a prospective trial to confirm the increased risk.

Matthew J. Budoff, MD describes bridging the gap between atherosclerosis and osteoporosis through advanced Imaging techniques.

Troum discussed the AGILE study and how DECT scanning helped visualize improvements in uncontrolled gout.

Stone discussed the phase 3 MITIGATE study, other potential treatment strategies, and top research priorities moving forward for IgG4.

Conaghan discussed findings from a phase 2 trial at the ACR 2024 Convergence.

At ACR, HCPLive spoke with Erin Treemarcki on a survey that showed many rheumatologists do not use established enthesitis scoring measures for children.

At ACR, HCPLive spoke with Ashima Makol, MD, about factors linked to a worse health-related quality of life in patients with early systemic sclerosis.

Emapalumab may improve outcomes in patients with MAS whose disease didn’t respond to steroid therapy and mitigate the need for more toxic therapies.

Arnold discussed his research in analyzing and improving current classifications of ANA-RMDs and how it could help improve research in the field.

Tesser discussed the background of the phase 3 RESET-RA trial and efficacy findings.

Noaiseh discussed data from the DAHLIAS study linking, for the first time, clinical responses, with autoantibody levels.

Gossec discussed findings from the PsABIOnd study presented at the 2024 ACR Convergence.

Just discussed data from 2 studies demonstrating efficacy of AI assessment compared to clinician assessment.